SynthesisDrug design, development and therapy2025
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis.
Synthesis in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis.Cancer metastasis reviews · 2026Pooled it
- PD-1/PD-L1 immune checkpoint inhibitors in Hodgkin lymphoma: A meta- and network meta-analysis.Translational oncology · 2026Review
- Preventing infusion-related reactions: the lessons learn with the use of amivantamab.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the incidence of Infusion-Related Reactions (IRRs) among cancer patients receiving Immune Checkpoint Inhibitors (ICIs) and immune-based combinations. Patients and Methods: The ARON-MOUSEION-013 was registered in PROSPERO (CRD420251018433). Observational, randomized and quasi-experimental studies were included in the present review, and rates in IRR among cancer adults (≥18 years) receiving ICIs were recorded and then analyzed. Results: A total of 4 records were considered for analyses, with a total of 55 observations and 35 events. The overall prevalence of IRR, considering Any Grade, was 67.4% [95% CI: 3.9%; 99.1%]. Considering Grade ≥ 3, a total of 55 observations and 8 events were registered. The overall prevalence of irAEs in IRRs was 6% [95% CI: 0.2%; 74.7%]. Conclusion: Mild-to-moderate IRRs are not rare events in patients receiving ICIs. IRRs may be avoided to manage these infusions slowly; however, severe reactions require emergency handling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.